Ubrogepant vs. Triptans: A New Hope for Migraine Relief

Research Summary

A recent study published in Pain Management explored the experiences of migraine sufferers switching from one oral triptan to either another triptan or ubrogepant. Conducted with participants using the Migraine Buddy app, the 4-week survey assessed treatment satisfaction and preferences. Out of 211 participants, those who switched to ubrogepant reported significantly higher satisfaction with pain relief (69.4% vs 42.0%) and alleviation of bothersome symptoms (69.4% vs 42.0%) compared to those who switched triptans. Additionally, 75.7% of the ubrogepant group preferred their new treatment over their previous triptan and experienced more meaningful relief within two hours (75.7% vs 59.0%).

Study Details

📄 Title: Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

👥 Research Team: Lipton RB et al.

📚 Published In: Pain Manag

📅 Publication Date: 2025 Nov 19

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.